

MEDIA RELEASE

Date 11 May 2022
Contact Investor Relations: Felix Burkhard, CFO Galenica Group
Media Relations: Christina Hertig, Head of Corporate Communications
Subject Annual General Meeting 2022 of Galenica Ltd.

5. Annual General Meeting of Galenica Ltd.: shareholders elected Judith Meier as a new member of the Board of Directors and approved all proposals.

The fifth Annual General Meeting of Galenica Ltd. was held on 11 May 2022 – with shareholders actually in attendance for the first time in two years – at the Kursaal in Bern. The shareholders approved all proposals put forward by the Board of Directors with more than 90% votes in favour. They therefore also approved the dividend proposal of CHF 2.10 per share, an increase of 17% from last year. The Annual General Meeting also elected Judith Meier as a new member of the Board of Directors; all other members were re-elected for a term of office of one year.

The fifth Annual General Meeting of Galenica Ltd. was attended by 313 shareholders, representing a total of 70.6% of the registered voting shares of Galenica Ltd.

Judith Meier elected as a new member of the Board of Directors

At the request of the Board of Directors, the Annual General Meeting elected Judith Meier (born 1962, Swiss citizen) as a new member of the Board of Directors of the Galenica Group. From 2009 to 2016, Judith Meier was CEO of Zurzach Care Ltd. (formerly the Reha Clinic Group) and was a Delegate (from 2017) and then Vice-Chairwoman (from 2019) of the Board of Directors of Zurzach Care Ltd. She is a co-founder of reha at home Ltd. (founded in 2018). From 1989 to 2001 she was a member of the Grand Council of the Canton of Aargau. With her proven expertise and valuable experience in strategically important areas of the Group's activities, Judith Meier is the perfect addition to the Board of Directors. Particularly for key topics of the strategic Care programme, such as home care, the development of health services and the needs and processes of care homes and clinics.

Strong dividend increase

The Annual General Meeting also approved the dividend of CHF 2.10 per share proposed by the Board of Directors, which is 17% higher than the previous year. Half (CHF 1.05 per share) is paid out from the capital contribution reserve and the other half from retained earnings. Overall, this corresponds to an expected distribution of CHF 104.2 million. With the increase of 17%, Galenica is ensuring shareholders share the benefit of the extremely successful 2021 financial year. Galenica strives for a strong yet sustainable dividend growth and plans to pay a dividend equal at least to the prior year's level in 2022. Dividends for the 2021 financial year will be paid out to shareholders from 17 May 2022 onwards.

Date 11 May 2022
Page 2/2
Subject Annual General Meeting 2022 of Galenica Ltd.

Approval of the 2021 financial statements and formal approval of the actions of the Board of Directors and Executive Committee

The shareholders also supported the proposals of the Board of Directors on all other agenda items. The 2021 financial statements of Galenica Ltd, as well as the Management Report and the consolidated financial statements of the Galenica Group for 2021 were approved, for example, and the actions of the members of the Board of Directors and Executive Committee were formally approved for the 2021 financial year. In a consultative vote, the shareholders approved the 2021 Remuneration Report with 88.9%. The proposed binding maximum total compensation for 2023 for members of the Board of Directors and Executive Committee was also approved with 89.9% and 89.4% votes in agreement respectively.

Re-elections and elections to the Board of Directors and re-elections to the Remuneration Committee

For a term of office of one year each, Daniela Bosshardt was re-elected as member and Chairwoman of the Board of Directors, while Bertrand Jungo, Pascale Bruderer, Prof. Michel Burnier, Dr Markus R. Neuhaus and Dr Andreas Walde were re-elected as members. Judith Meier was elected as a new member for a term of office of one year.

For a term of office of one year, Dr Andreas Walde, Dr Markus R. Neuhaus and Prof. Hon. Dr Michel Burnier were re-elected to the Remuneration Committee, with Dr Andreas Walde reappointed as Chairman by the Board of Directors.

Dates for the diary

9 August 2022:	publication of the Galenica Group half-year report 2022
19 January 2023:	2022 sales of the Galenica Group
7 March 2023:	publication of the Galenica Group results 2022
3 May 2023:	Annual General Meeting of Galenica Ltd.

For further information, please contact:

Media Relations:

Christina Hertig, Head of Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Galenica is Switzerland's leading, completely integrated healthcare service provider. With over 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of pre-wholesale and wholesale distribution services as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning Galenica can be found at www.galenica.com.